repliderm inc. · group 8 tiwalade ashaye, joseph azzarello, ben fairbanks, mitch hargis, krupa...
TRANSCRIPT
![Page 1: REPLIDERM Inc. · GROUP 8 Tiwalade Ashaye, Joseph Azzarello, Ben Fairbanks, Mitch Hargis, Krupa Patel, Holap Tang . OVERVIEW zBackground/Review of current conditions ... 220 50 C](https://reader035.vdocuments.site/reader035/viewer/2022071006/5fc33613a3ab2c04576459bb/html5/thumbnails/1.jpg)
REPLIDERM Inc.REPLIDERM Inc.
GROUP 8
Tiwalade Ashaye, Joseph Azzarello,
Ben Fairbanks, Mitch Hargis,Krupa Patel, Holap Tang
![Page 2: REPLIDERM Inc. · GROUP 8 Tiwalade Ashaye, Joseph Azzarello, Ben Fairbanks, Mitch Hargis, Krupa Patel, Holap Tang . OVERVIEW zBackground/Review of current conditions ... 220 50 C](https://reader035.vdocuments.site/reader035/viewer/2022071006/5fc33613a3ab2c04576459bb/html5/thumbnails/2.jpg)
OVERVIEWOVERVIEW
Background/Review of current conditionsObjective of RepliDermProduction planFDA Approval ProcessBusiness/Market Plan
![Page 3: REPLIDERM Inc. · GROUP 8 Tiwalade Ashaye, Joseph Azzarello, Ben Fairbanks, Mitch Hargis, Krupa Patel, Holap Tang . OVERVIEW zBackground/Review of current conditions ... 220 50 C](https://reader035.vdocuments.site/reader035/viewer/2022071006/5fc33613a3ab2c04576459bb/html5/thumbnails/3.jpg)
BACKGROUNDBACKGROUND
![Page 4: REPLIDERM Inc. · GROUP 8 Tiwalade Ashaye, Joseph Azzarello, Ben Fairbanks, Mitch Hargis, Krupa Patel, Holap Tang . OVERVIEW zBackground/Review of current conditions ... 220 50 C](https://reader035.vdocuments.site/reader035/viewer/2022071006/5fc33613a3ab2c04576459bb/html5/thumbnails/4.jpg)
ProblemProblem
270,000 burn victims per year in the U.S. requiring hospitalization1.5 million diabetic patients in the U.S. with wound ulcersVarious narcotizing infections (flesh eating infections)
![Page 5: REPLIDERM Inc. · GROUP 8 Tiwalade Ashaye, Joseph Azzarello, Ben Fairbanks, Mitch Hargis, Krupa Patel, Holap Tang . OVERVIEW zBackground/Review of current conditions ... 220 50 C](https://reader035.vdocuments.site/reader035/viewer/2022071006/5fc33613a3ab2c04576459bb/html5/thumbnails/5.jpg)
Treatments AvailableTreatments Available
Split thickness autograftDonor allograftSynthetic allograftSynthetic allograft with seeded neo-natal fibroblastsTemporary covering from biological donor
![Page 6: REPLIDERM Inc. · GROUP 8 Tiwalade Ashaye, Joseph Azzarello, Ben Fairbanks, Mitch Hargis, Krupa Patel, Holap Tang . OVERVIEW zBackground/Review of current conditions ... 220 50 C](https://reader035.vdocuments.site/reader035/viewer/2022071006/5fc33613a3ab2c04576459bb/html5/thumbnails/6.jpg)
Advantages of Existing Advantages of Existing TreatmentsTreatments
$42/in2Epidermal autograft required
Strong & suppleProtective layer5% Rejection
Synthetic (Integra)
$102/in2Fragile No epidermal graft needed
5% Rejection
Synthetic Allograft with Seeded Cells (Epicel)
$7/in2Disease transmission10% RejectionSmall wounds only
Relatively Inexpensive
Donor Allograft (AlloDerm)
$0Extensive scarringLimited donor sites
Inexpensive No rejection
Split Thickness Autograft (Surgical treatment)
Price/in2DisadvantagesAdvantagesProcedure(Product)
![Page 7: REPLIDERM Inc. · GROUP 8 Tiwalade Ashaye, Joseph Azzarello, Ben Fairbanks, Mitch Hargis, Krupa Patel, Holap Tang . OVERVIEW zBackground/Review of current conditions ... 220 50 C](https://reader035.vdocuments.site/reader035/viewer/2022071006/5fc33613a3ab2c04576459bb/html5/thumbnails/7.jpg)
On the Market: Integra Dermal On the Market: Integra Dermal Regeneration TemplateRegeneration Template
![Page 8: REPLIDERM Inc. · GROUP 8 Tiwalade Ashaye, Joseph Azzarello, Ben Fairbanks, Mitch Hargis, Krupa Patel, Holap Tang . OVERVIEW zBackground/Review of current conditions ... 220 50 C](https://reader035.vdocuments.site/reader035/viewer/2022071006/5fc33613a3ab2c04576459bb/html5/thumbnails/8.jpg)
On the Market: Integra Dermal On the Market: Integra Dermal Regeneration TemplateRegeneration Template
![Page 9: REPLIDERM Inc. · GROUP 8 Tiwalade Ashaye, Joseph Azzarello, Ben Fairbanks, Mitch Hargis, Krupa Patel, Holap Tang . OVERVIEW zBackground/Review of current conditions ... 220 50 C](https://reader035.vdocuments.site/reader035/viewer/2022071006/5fc33613a3ab2c04576459bb/html5/thumbnails/9.jpg)
Mechanism for AngiogenesisMechanism for Angiogenesis
![Page 10: REPLIDERM Inc. · GROUP 8 Tiwalade Ashaye, Joseph Azzarello, Ben Fairbanks, Mitch Hargis, Krupa Patel, Holap Tang . OVERVIEW zBackground/Review of current conditions ... 220 50 C](https://reader035.vdocuments.site/reader035/viewer/2022071006/5fc33613a3ab2c04576459bb/html5/thumbnails/10.jpg)
On the Market: Integra Dermal On the Market: Integra Dermal Regeneration TemplateRegeneration Template
![Page 11: REPLIDERM Inc. · GROUP 8 Tiwalade Ashaye, Joseph Azzarello, Ben Fairbanks, Mitch Hargis, Krupa Patel, Holap Tang . OVERVIEW zBackground/Review of current conditions ... 220 50 C](https://reader035.vdocuments.site/reader035/viewer/2022071006/5fc33613a3ab2c04576459bb/html5/thumbnails/11.jpg)
On the Market: Integra Dermal On the Market: Integra Dermal Regeneration TemplateRegeneration Template
![Page 12: REPLIDERM Inc. · GROUP 8 Tiwalade Ashaye, Joseph Azzarello, Ben Fairbanks, Mitch Hargis, Krupa Patel, Holap Tang . OVERVIEW zBackground/Review of current conditions ... 220 50 C](https://reader035.vdocuments.site/reader035/viewer/2022071006/5fc33613a3ab2c04576459bb/html5/thumbnails/12.jpg)
On the Market: Integra Dermal Regeneration Template
![Page 13: REPLIDERM Inc. · GROUP 8 Tiwalade Ashaye, Joseph Azzarello, Ben Fairbanks, Mitch Hargis, Krupa Patel, Holap Tang . OVERVIEW zBackground/Review of current conditions ... 220 50 C](https://reader035.vdocuments.site/reader035/viewer/2022071006/5fc33613a3ab2c04576459bb/html5/thumbnails/13.jpg)
Product ObjectiveProduct Objective
To produce a synthetic dermal replacement template that increases the speed of vascularization and quality of burn and wound treatment.
![Page 14: REPLIDERM Inc. · GROUP 8 Tiwalade Ashaye, Joseph Azzarello, Ben Fairbanks, Mitch Hargis, Krupa Patel, Holap Tang . OVERVIEW zBackground/Review of current conditions ... 220 50 C](https://reader035.vdocuments.site/reader035/viewer/2022071006/5fc33613a3ab2c04576459bb/html5/thumbnails/14.jpg)
Growth FactorsGrowth Factors
Basic Fibroblast Growth Factor-BFGFAcidic Fibroblast Growth Factor-AFGFPlatelets Derived Growth Factor-PDGFVascular Endothelial Growth Factor-VEGF
![Page 15: REPLIDERM Inc. · GROUP 8 Tiwalade Ashaye, Joseph Azzarello, Ben Fairbanks, Mitch Hargis, Krupa Patel, Holap Tang . OVERVIEW zBackground/Review of current conditions ... 220 50 C](https://reader035.vdocuments.site/reader035/viewer/2022071006/5fc33613a3ab2c04576459bb/html5/thumbnails/15.jpg)
VEGF Stimulation of Angiogenesis
VEGFR2
VEGF
PLCγ1PI3 kinase
Morphogenesis Cell Proliferation
![Page 16: REPLIDERM Inc. · GROUP 8 Tiwalade Ashaye, Joseph Azzarello, Ben Fairbanks, Mitch Hargis, Krupa Patel, Holap Tang . OVERVIEW zBackground/Review of current conditions ... 220 50 C](https://reader035.vdocuments.site/reader035/viewer/2022071006/5fc33613a3ab2c04576459bb/html5/thumbnails/16.jpg)
Methods of Delivery
Daily InjectionsVEGF in the crosslinked collagen matrixVEGF in suspension in pores of matrixControlled release microparticles
![Page 17: REPLIDERM Inc. · GROUP 8 Tiwalade Ashaye, Joseph Azzarello, Ben Fairbanks, Mitch Hargis, Krupa Patel, Holap Tang . OVERVIEW zBackground/Review of current conditions ... 220 50 C](https://reader035.vdocuments.site/reader035/viewer/2022071006/5fc33613a3ab2c04576459bb/html5/thumbnails/17.jpg)
Controlled Release particlesControlled Release particles
Optimize rate of vascularization by altering:– Number/VEGF Concentration of
Microcapsules– Location of Microcapsules– Size of Microcapsules
![Page 18: REPLIDERM Inc. · GROUP 8 Tiwalade Ashaye, Joseph Azzarello, Ben Fairbanks, Mitch Hargis, Krupa Patel, Holap Tang . OVERVIEW zBackground/Review of current conditions ... 220 50 C](https://reader035.vdocuments.site/reader035/viewer/2022071006/5fc33613a3ab2c04576459bb/html5/thumbnails/18.jpg)
Microcapsule Diffusion ModelMicrocapsule Diffusion Model
A model of the VEGF’s motion through the implant could be created and used to create a more-effective productIf a model with predictive capabilities was created, then the ideal initial concentration and placement of the microbeads could be determined
![Page 19: REPLIDERM Inc. · GROUP 8 Tiwalade Ashaye, Joseph Azzarello, Ben Fairbanks, Mitch Hargis, Krupa Patel, Holap Tang . OVERVIEW zBackground/Review of current conditions ... 220 50 C](https://reader035.vdocuments.site/reader035/viewer/2022071006/5fc33613a3ab2c04576459bb/html5/thumbnails/19.jpg)
Z=y(t)
Z=-L at y(0)
Microcapsule Diffusion Model
No flux across top layer: (δc/δz = 0 @ z=L)Bottom layer rises with time as tissue vascularizes into graftLiving tissue carries away VEGF with a rate kvf(c3)Regions 1,2, and 3 have a diffusion coefficient D1Region #4 has diffusion coefficient D2Molar fluxes are equal at region interfaces
Layer containing Microbeads (#2)
Living Tissue (Region #4)
Region #1
Region #3
Z=0
Z=+L
Microbead region releases VEGF with
rate r* and at a concentration c*
![Page 20: REPLIDERM Inc. · GROUP 8 Tiwalade Ashaye, Joseph Azzarello, Ben Fairbanks, Mitch Hargis, Krupa Patel, Holap Tang . OVERVIEW zBackground/Review of current conditions ... 220 50 C](https://reader035.vdocuments.site/reader035/viewer/2022071006/5fc33613a3ab2c04576459bb/html5/thumbnails/20.jpg)
Microcapsule Diffusion ModelMicrocapsule Diffusion Model
With the model described in the previous slide, the following expression is obtained:
y(t) (the “rate of healing”) can be approximated from the above model
ty
g ekrk
dtdy
3
2* α−
=
![Page 21: REPLIDERM Inc. · GROUP 8 Tiwalade Ashaye, Joseph Azzarello, Ben Fairbanks, Mitch Hargis, Krupa Patel, Holap Tang . OVERVIEW zBackground/Review of current conditions ... 220 50 C](https://reader035.vdocuments.site/reader035/viewer/2022071006/5fc33613a3ab2c04576459bb/html5/thumbnails/21.jpg)
PRODUCTION PROCESSPRODUCTION PROCESS
![Page 22: REPLIDERM Inc. · GROUP 8 Tiwalade Ashaye, Joseph Azzarello, Ben Fairbanks, Mitch Hargis, Krupa Patel, Holap Tang . OVERVIEW zBackground/Review of current conditions ... 220 50 C](https://reader035.vdocuments.site/reader035/viewer/2022071006/5fc33613a3ab2c04576459bb/html5/thumbnails/22.jpg)
![Page 23: REPLIDERM Inc. · GROUP 8 Tiwalade Ashaye, Joseph Azzarello, Ben Fairbanks, Mitch Hargis, Krupa Patel, Holap Tang . OVERVIEW zBackground/Review of current conditions ... 220 50 C](https://reader035.vdocuments.site/reader035/viewer/2022071006/5fc33613a3ab2c04576459bb/html5/thumbnails/23.jpg)
REPLIDERM PRODUCTIONREPLIDERM PRODUCTION
Raw material neededEquipments neededDescription of processHuman labor neededFacility layout
![Page 24: REPLIDERM Inc. · GROUP 8 Tiwalade Ashaye, Joseph Azzarello, Ben Fairbanks, Mitch Hargis, Krupa Patel, Holap Tang . OVERVIEW zBackground/Review of current conditions ... 220 50 C](https://reader035.vdocuments.site/reader035/viewer/2022071006/5fc33613a3ab2c04576459bb/html5/thumbnails/24.jpg)
REPLIDERM ProductionREPLIDERM Production
Raw materials neededEquipments neededDescription of processHuman labor neededFacility layout
![Page 25: REPLIDERM Inc. · GROUP 8 Tiwalade Ashaye, Joseph Azzarello, Ben Fairbanks, Mitch Hargis, Krupa Patel, Holap Tang . OVERVIEW zBackground/Review of current conditions ... 220 50 C](https://reader035.vdocuments.site/reader035/viewer/2022071006/5fc33613a3ab2c04576459bb/html5/thumbnails/25.jpg)
REPLIDERM ProductionREPLIDERM Production(Raw materials)(Raw materials)
Manufacture of microspheresBiodegradable, biocompatible polyester
PLGA( polylactic glycolic acid
Speeds up degradation of the microbeads. It also forms the sphere shape of the beads
Polymer PEG(Polyethylene-
glycol)A protein growth factorAs described earlierVEGF
Used as a temporary barrier to protect against infection
Silicon layerSilastic
forms the ground substance in the extracellular matrix of connective tissue.
Glycoproteins known as proteoglycans found in shark cartilage
Chondroitin6-Sulfate
Support and structure of matirxExtracellular proteinBovineCollagen
UseDescriptionProcedure(Product)
![Page 26: REPLIDERM Inc. · GROUP 8 Tiwalade Ashaye, Joseph Azzarello, Ben Fairbanks, Mitch Hargis, Krupa Patel, Holap Tang . OVERVIEW zBackground/Review of current conditions ... 220 50 C](https://reader035.vdocuments.site/reader035/viewer/2022071006/5fc33613a3ab2c04576459bb/html5/thumbnails/26.jpg)
REPLIDERM ProductionREPLIDERM Production
Raw material needed
Equipments neededDescription of ProcessHuman labor neededFacility layout
![Page 27: REPLIDERM Inc. · GROUP 8 Tiwalade Ashaye, Joseph Azzarello, Ben Fairbanks, Mitch Hargis, Krupa Patel, Holap Tang . OVERVIEW zBackground/Review of current conditions ... 220 50 C](https://reader035.vdocuments.site/reader035/viewer/2022071006/5fc33613a3ab2c04576459bb/html5/thumbnails/27.jpg)
Repliderm Production(Equipments Needed)
Small EquipmentBatch processes
Blender Tissue Homogenizer
Vacuum oven VortexCentrifuge
![Page 28: REPLIDERM Inc. · GROUP 8 Tiwalade Ashaye, Joseph Azzarello, Ben Fairbanks, Mitch Hargis, Krupa Patel, Holap Tang . OVERVIEW zBackground/Review of current conditions ... 220 50 C](https://reader035.vdocuments.site/reader035/viewer/2022071006/5fc33613a3ab2c04576459bb/html5/thumbnails/28.jpg)
REPLIDERM ProductionREPLIDERM Production
Raw material neededEquipments needed
Description of ProcessHuman labor neededFacility layout
![Page 29: REPLIDERM Inc. · GROUP 8 Tiwalade Ashaye, Joseph Azzarello, Ben Fairbanks, Mitch Hargis, Krupa Patel, Holap Tang . OVERVIEW zBackground/Review of current conditions ... 220 50 C](https://reader035.vdocuments.site/reader035/viewer/2022071006/5fc33613a3ab2c04576459bb/html5/thumbnails/29.jpg)
![Page 30: REPLIDERM Inc. · GROUP 8 Tiwalade Ashaye, Joseph Azzarello, Ben Fairbanks, Mitch Hargis, Krupa Patel, Holap Tang . OVERVIEW zBackground/Review of current conditions ... 220 50 C](https://reader035.vdocuments.site/reader035/viewer/2022071006/5fc33613a3ab2c04576459bb/html5/thumbnails/30.jpg)
Before Microbead additionBefore Microbead addition……
![Page 31: REPLIDERM Inc. · GROUP 8 Tiwalade Ashaye, Joseph Azzarello, Ben Fairbanks, Mitch Hargis, Krupa Patel, Holap Tang . OVERVIEW zBackground/Review of current conditions ... 220 50 C](https://reader035.vdocuments.site/reader035/viewer/2022071006/5fc33613a3ab2c04576459bb/html5/thumbnails/31.jpg)
![Page 32: REPLIDERM Inc. · GROUP 8 Tiwalade Ashaye, Joseph Azzarello, Ben Fairbanks, Mitch Hargis, Krupa Patel, Holap Tang . OVERVIEW zBackground/Review of current conditions ... 220 50 C](https://reader035.vdocuments.site/reader035/viewer/2022071006/5fc33613a3ab2c04576459bb/html5/thumbnails/32.jpg)
After Microbead additionAfter Microbead addition……
![Page 33: REPLIDERM Inc. · GROUP 8 Tiwalade Ashaye, Joseph Azzarello, Ben Fairbanks, Mitch Hargis, Krupa Patel, Holap Tang . OVERVIEW zBackground/Review of current conditions ... 220 50 C](https://reader035.vdocuments.site/reader035/viewer/2022071006/5fc33613a3ab2c04576459bb/html5/thumbnails/33.jpg)
Microcapsule ProductionMicrocapsule Production
Raw materials -• PLGA Poly(lactic-co-glycolic) acid (50:50)• PEG (Polyethylene- glycol)• VEGF (Vascular endothelial growth factor)• Albumin• PVA (polyvinyl alcohol)• Isopropanol
![Page 34: REPLIDERM Inc. · GROUP 8 Tiwalade Ashaye, Joseph Azzarello, Ben Fairbanks, Mitch Hargis, Krupa Patel, Holap Tang . OVERVIEW zBackground/Review of current conditions ... 220 50 C](https://reader035.vdocuments.site/reader035/viewer/2022071006/5fc33613a3ab2c04576459bb/html5/thumbnails/34.jpg)
MICROCAPSULE PRODUCTION
![Page 35: REPLIDERM Inc. · GROUP 8 Tiwalade Ashaye, Joseph Azzarello, Ben Fairbanks, Mitch Hargis, Krupa Patel, Holap Tang . OVERVIEW zBackground/Review of current conditions ... 220 50 C](https://reader035.vdocuments.site/reader035/viewer/2022071006/5fc33613a3ab2c04576459bb/html5/thumbnails/35.jpg)
REPLIDERM ProductionREPLIDERM Production
Human Labor Needed– Minimum – 1PhD, 3 technical
assistantsFacility Layout (30,000sq-ft)– 1 cryo room, Storage, Offices,
Animal storage, Laboratory testing, 2 Production rooms
![Page 36: REPLIDERM Inc. · GROUP 8 Tiwalade Ashaye, Joseph Azzarello, Ben Fairbanks, Mitch Hargis, Krupa Patel, Holap Tang . OVERVIEW zBackground/Review of current conditions ... 220 50 C](https://reader035.vdocuments.site/reader035/viewer/2022071006/5fc33613a3ab2c04576459bb/html5/thumbnails/36.jpg)
Quality Control
• 1% of all sheets produced to be selected at random and tested for quality assurances– All of sheets to be tested are
halved. Half of each sheet are tested on a chorioallantoic membrane.
– The remaining halves are tested in vitro with vascular endothelial cells
![Page 37: REPLIDERM Inc. · GROUP 8 Tiwalade Ashaye, Joseph Azzarello, Ben Fairbanks, Mitch Hargis, Krupa Patel, Holap Tang . OVERVIEW zBackground/Review of current conditions ... 220 50 C](https://reader035.vdocuments.site/reader035/viewer/2022071006/5fc33613a3ab2c04576459bb/html5/thumbnails/37.jpg)
FDA PROCESSFDA PROCESS
![Page 38: REPLIDERM Inc. · GROUP 8 Tiwalade Ashaye, Joseph Azzarello, Ben Fairbanks, Mitch Hargis, Krupa Patel, Holap Tang . OVERVIEW zBackground/Review of current conditions ... 220 50 C](https://reader035.vdocuments.site/reader035/viewer/2022071006/5fc33613a3ab2c04576459bb/html5/thumbnails/38.jpg)
FDA Approval Process
• Most costly and time consuming step in bringing a new product to market.REPLIDERM is a Class III medical device. Class III medical devices are those that are implanted into a patient and left in the body.
Non-clinical testingManufacturing and facility testingClinical testing
![Page 39: REPLIDERM Inc. · GROUP 8 Tiwalade Ashaye, Joseph Azzarello, Ben Fairbanks, Mitch Hargis, Krupa Patel, Holap Tang . OVERVIEW zBackground/Review of current conditions ... 220 50 C](https://reader035.vdocuments.site/reader035/viewer/2022071006/5fc33613a3ab2c04576459bb/html5/thumbnails/39.jpg)
FDA Approval Process
•Modular Pre-Market Approval Process•Module 1: Non-clinical Trials•Module 2: Manufacturing & Facility
Testing•Module 3: Human Clinical Trials
![Page 40: REPLIDERM Inc. · GROUP 8 Tiwalade Ashaye, Joseph Azzarello, Ben Fairbanks, Mitch Hargis, Krupa Patel, Holap Tang . OVERVIEW zBackground/Review of current conditions ... 220 50 C](https://reader035.vdocuments.site/reader035/viewer/2022071006/5fc33613a3ab2c04576459bb/html5/thumbnails/40.jpg)
FDA Testing
Historically FDA testing requires $200,000,000 to $300,000,000 and can last 10-15 years.It is this cost and time delay the FDA testing is the most critical step in bringing a new product to the market.
![Page 41: REPLIDERM Inc. · GROUP 8 Tiwalade Ashaye, Joseph Azzarello, Ben Fairbanks, Mitch Hargis, Krupa Patel, Holap Tang . OVERVIEW zBackground/Review of current conditions ... 220 50 C](https://reader035.vdocuments.site/reader035/viewer/2022071006/5fc33613a3ab2c04576459bb/html5/thumbnails/41.jpg)
First Stage Variables
A 1st Stage Variable is a decision that must be made before any production begins.For our project, we have two 1st Stage Variables:– The number of personnel to hire– The number of experiments to run before
submitting our product to FDA evaluation.
![Page 42: REPLIDERM Inc. · GROUP 8 Tiwalade Ashaye, Joseph Azzarello, Ben Fairbanks, Mitch Hargis, Krupa Patel, Holap Tang . OVERVIEW zBackground/Review of current conditions ... 220 50 C](https://reader035.vdocuments.site/reader035/viewer/2022071006/5fc33613a3ab2c04576459bb/html5/thumbnails/42.jpg)
Second Stage Variables
A 2nd Stage Variable is a decision that is made after an outcome.For our project, we have several 2nd Stage Variables:– Each 2nd Stage Variable is a choice on
whether or not to continue after an FDA Failure.
– The chance of having an FDA Failure is dependent on the amount of tests conducted prior to FDA review.
![Page 43: REPLIDERM Inc. · GROUP 8 Tiwalade Ashaye, Joseph Azzarello, Ben Fairbanks, Mitch Hargis, Krupa Patel, Holap Tang . OVERVIEW zBackground/Review of current conditions ... 220 50 C](https://reader035.vdocuments.site/reader035/viewer/2022071006/5fc33613a3ab2c04576459bb/html5/thumbnails/43.jpg)
First Stage Variable
Number of Personnel Options:– 1 Ph.D. and 3 Lab Technicians– 1 Ph.D. and 5 Lab Technicians– 1 Ph.D. and 7 Lab Technicians
Number of Experiments to Run Prior to submission to FDA review:
2525505050 50C50505050100100B100100100100100100A
DogsPigsGuinea Pigs
Nude Mice
CAM Tests
Cell Tests
Set
![Page 44: REPLIDERM Inc. · GROUP 8 Tiwalade Ashaye, Joseph Azzarello, Ben Fairbanks, Mitch Hargis, Krupa Patel, Holap Tang . OVERVIEW zBackground/Review of current conditions ... 220 50 C](https://reader035.vdocuments.site/reader035/viewer/2022071006/5fc33613a3ab2c04576459bb/html5/thumbnails/44.jpg)
Second Decision (First Stage Variable)
Lest costly, but higher likelihood of being forced to repeat some FDA trials.
50 Cell Flask, 50 CAM,50 Nude Mice, 50 Guinea Pig, 25 Pig, 25 Dog Tests
Set C
Compromise on time and money, but the chances of passing FDA are less than A.
100 Cell Flask, 100 CAM,50 Nude Mice, 50 Guinea Pig, 50 Pig, 50 Dog Tests
Set B
More time and money spent up front, but higher likelihood of passing FDA trials on 1st try.
100 Cell Flask, 100 CAM,100 Nude Mice, 100 Guinea Pig, 100 Pig, 100 Dog Tests
Set A
DescriptionDescriptionSet
![Page 45: REPLIDERM Inc. · GROUP 8 Tiwalade Ashaye, Joseph Azzarello, Ben Fairbanks, Mitch Hargis, Krupa Patel, Holap Tang . OVERVIEW zBackground/Review of current conditions ... 220 50 C](https://reader035.vdocuments.site/reader035/viewer/2022071006/5fc33613a3ab2c04576459bb/html5/thumbnails/45.jpg)
Initial Grant Money
The initial amount of grant money that we obtain will be the deciding factor in which employment option and which testing option we choose.Initial grant money will be obtained from the NIH, NSF, CDC, and other various government granting agencies.
![Page 46: REPLIDERM Inc. · GROUP 8 Tiwalade Ashaye, Joseph Azzarello, Ben Fairbanks, Mitch Hargis, Krupa Patel, Holap Tang . OVERVIEW zBackground/Review of current conditions ... 220 50 C](https://reader035.vdocuments.site/reader035/viewer/2022071006/5fc33613a3ab2c04576459bb/html5/thumbnails/46.jpg)
FDA APPROVALS t a r t
N u m b e r o fp e r s o n n e l
1 P h D & 3 T e c h n i c i a n sS a l a r y : $ 2 0 5 , 0 0 0 / y r
W o r k i n g h r : 2 4 h r s / d a y
1 P h D & 5 T e c h n i c i a n sS a l a r y : $ 2 7 5 , 0 0 0 / y r
W o r k i n g h r : 4 0 h r s / d a y
1 P h D & 7 T e c h n i c i a n sS a l a r y : $ 3 4 5 , 0 0 0 / y r
W o r k i n g h r : 5 6 h r s / d a y
N u m b e r o fe x p e r i m e n t s
r u n
1 0 0 C e l l - F l a s kT e s t s
1 0 0 C A M T e s t sD a y s : 2 7 0
5 0 C e l l - F l a s kT e s t s
1 0 0 C A M T e s t sD a y s : 2 2 0
5 0 C e l l - F l a s kT e s t s
5 0 C A M T e s t sD a y s : 1 4 5
N u m b e r o fe x p e r i m e n t s
r u n
N u m b e r o fe x p e r i m e n t s
r u n
F D A
1 0 0 C e l l - F l a s kT e s t s
1 0 0 C A M T e s t sD a y s : 1 6 0
5 0 C e l l - F l a s kT e s t s
1 0 0 C A M T e s t sD a y s : 1 3 0
5 0 C e l l - F l a s kT e s t s
5 0 C A M T e s t sD a y s : 9 0
1 0 0 C e l l - F l a s kT e s t s
1 0 0 C A M T e s t sD a y s : 1 2 0
5 0 C e l l - F l a s kT e s t s
1 0 0 C A M T e s t sD a y s : 9 5
5 0 C e l l - F l a s kT e s t s
5 0 C A M T e s t sD a y s : 6 0
P r e - M a r k e t A p p r o v a lA p p l i c a t i o n R e v i e w
C o s t : $ 5 0 , 0 0 0T i m e : 5 5 D a y s
A p p r o v a l9 0 % c h a n c e
F a i l u r e D u e t o M a r k e t L i m i t a t i o n s5 %
F a i l u r e D u e t o V a g u e n e s s o f A p p l i c a t i o n5 %
R e a p p l y f o r P M A ?G r a n t > $ 5 0 , 0 0 0
R e - A p p l y f o r P r e - M a r k e tA p p r o v a l R e v i e w
C o s t : $ 5 0 , 0 0 0T i m e : 5 5 D a y s
Y e s
S c r a p P r o j e c tC o s t : $ 0
N o
P r e - M a r k e t A p p r o v a l
A p p r o v a l9 9 % c h a n c e
F a i l u r e1 %
F i l e P M A A p p l i c a t i o nC o s t : $ 0
T i m e : 0 D a y s
S c r a p P r o j e c tC o s t : $ 0
M o d u l e 1 T e s t i n gC o s t : $ 5 0 0 , 0 0 0T i m e : 2 Y e a r s
A p p r o v a l7 0 %
C h a n g e c o n c e n t r a t i o no f V E G F
C o s t : $ 6 0 0 0T i m e : 2 d a y s
M o d i f y n o . o f m i c r o b e a dC o s t : $ 1 5 , 0 0 0T i m e : 3 d a y s
M i c r o b e a d F a i l u r e d u e t oc h a n g e o f c o n c . O f V E G F
1 0 %F a i l u r e d u e t o t h e n o . o f m i c r o b e a d
1 0 %
C h a n g e l o c a t i o n o fm i c r o b e a d
C o s t : $ 2 5 0 0T i m e : 3 d a y s
F a i l u r e d u e t ot h e l o c a t i o n o f t h e b e a d
1 0 %
C o n t i n u e ?G r a n t
> $ 5 0 0 , 0 0 0
S c r a p C o n t i n u e ?G r a n t
> $ 5 0 0 , 0 0 0
C o n t i n u e ?G r a n t
> $ 5 0 0 , 0 0 0
S c r a pS c r a p
![Page 47: REPLIDERM Inc. · GROUP 8 Tiwalade Ashaye, Joseph Azzarello, Ben Fairbanks, Mitch Hargis, Krupa Patel, Holap Tang . OVERVIEW zBackground/Review of current conditions ... 220 50 C](https://reader035.vdocuments.site/reader035/viewer/2022071006/5fc33613a3ab2c04576459bb/html5/thumbnails/47.jpg)
First Decision (First Stage Variable)
![Page 48: REPLIDERM Inc. · GROUP 8 Tiwalade Ashaye, Joseph Azzarello, Ben Fairbanks, Mitch Hargis, Krupa Patel, Holap Tang . OVERVIEW zBackground/Review of current conditions ... 220 50 C](https://reader035.vdocuments.site/reader035/viewer/2022071006/5fc33613a3ab2c04576459bb/html5/thumbnails/48.jpg)
Selection of Employees
Decision is based on the amount of initial grant money available.The more technicians the shorter the time required to run the same amount of test.
![Page 49: REPLIDERM Inc. · GROUP 8 Tiwalade Ashaye, Joseph Azzarello, Ben Fairbanks, Mitch Hargis, Krupa Patel, Holap Tang . OVERVIEW zBackground/Review of current conditions ... 220 50 C](https://reader035.vdocuments.site/reader035/viewer/2022071006/5fc33613a3ab2c04576459bb/html5/thumbnails/49.jpg)
Second Decision (First Stage Variable)
![Page 50: REPLIDERM Inc. · GROUP 8 Tiwalade Ashaye, Joseph Azzarello, Ben Fairbanks, Mitch Hargis, Krupa Patel, Holap Tang . OVERVIEW zBackground/Review of current conditions ... 220 50 C](https://reader035.vdocuments.site/reader035/viewer/2022071006/5fc33613a3ab2c04576459bb/html5/thumbnails/50.jpg)
Selection of Experiments
Set A - more experiments run concurrently, more in-depth testing and increasing the chances of passing the FDA trials on the 1st try.Set C - costs the least, begins the FDA testing quicker, but a higher likelihood of failure.All sets of experiments perform the same types of tests.
![Page 51: REPLIDERM Inc. · GROUP 8 Tiwalade Ashaye, Joseph Azzarello, Ben Fairbanks, Mitch Hargis, Krupa Patel, Holap Tang . OVERVIEW zBackground/Review of current conditions ... 220 50 C](https://reader035.vdocuments.site/reader035/viewer/2022071006/5fc33613a3ab2c04576459bb/html5/thumbnails/51.jpg)
Failure in FDA Approval (Second Stage Decision)
![Page 52: REPLIDERM Inc. · GROUP 8 Tiwalade Ashaye, Joseph Azzarello, Ben Fairbanks, Mitch Hargis, Krupa Patel, Holap Tang . OVERVIEW zBackground/Review of current conditions ... 220 50 C](https://reader035.vdocuments.site/reader035/viewer/2022071006/5fc33613a3ab2c04576459bb/html5/thumbnails/52.jpg)
Example: Module 1 Failure
![Page 53: REPLIDERM Inc. · GROUP 8 Tiwalade Ashaye, Joseph Azzarello, Ben Fairbanks, Mitch Hargis, Krupa Patel, Holap Tang . OVERVIEW zBackground/Review of current conditions ... 220 50 C](https://reader035.vdocuments.site/reader035/viewer/2022071006/5fc33613a3ab2c04576459bb/html5/thumbnails/53.jpg)
Fixing a Failure with the Concentration of VEGF in the Microbeads
Cost of Fixing:– $12,000 total– $6,000 for beads themselves– $2,000 for cell and CAM tests– $2,000 for small animal tests– $2,000 for labor
Time required is 14 days:– Cell, CAM, and small animal tests will be run
concurrently
![Page 54: REPLIDERM Inc. · GROUP 8 Tiwalade Ashaye, Joseph Azzarello, Ben Fairbanks, Mitch Hargis, Krupa Patel, Holap Tang . OVERVIEW zBackground/Review of current conditions ... 220 50 C](https://reader035.vdocuments.site/reader035/viewer/2022071006/5fc33613a3ab2c04576459bb/html5/thumbnails/54.jpg)
Example: PathwayStart
Number ofpersonnel
1 PhD & 3 TechniciansSalary: $205,000/yr
Working hr: 24hrs/day
1 PhD & 5 TechniciansSalary: $275,000/yr
Working hr: 40hrs/day
1 PhD & 7 TechniciansSalary: $345,000/yr
Working hr: 56hrs/day
Number ofexperiments
run
100 Cell-FlaskTests
100 CAM TestsDays: 270
50 Cell-FlaskTests
100 CAM TestsDays: 220
50 Cell-FlaskTests
50 CAM TestsDays: 145
Number ofexperiments
run
Number ofexperiments
run
FDA
100 Cell-FlaskTests
100 CAM TestsDays: 160
50 Cell-FlaskTests
100 CAM TestsDays: 130
50 Cell-FlaskTests
50 CAM TestsDays: 90
100 Cell-FlaskTests
100 CAM TestsDays: 120
50 Cell-FlaskTests
100 CAM TestsDays: 95
50 Cell-FlaskTests
50 CAM TestsDays: 60
Pre-Market ApprovalApplication Review
Cost: $50,000Time: 55 Days
Approval90% chance
Failure Due to Market Limitations5%
Failure Due to Vagueness of Application5%
Reapply for PMA?Grant > $50,000
Yes No
![Page 55: REPLIDERM Inc. · GROUP 8 Tiwalade Ashaye, Joseph Azzarello, Ben Fairbanks, Mitch Hargis, Krupa Patel, Holap Tang . OVERVIEW zBackground/Review of current conditions ... 220 50 C](https://reader035.vdocuments.site/reader035/viewer/2022071006/5fc33613a3ab2c04576459bb/html5/thumbnails/55.jpg)
FDA Decision
9 decisionsEach decision contains 738 pathwaysTotal pathways: 6642 pathwayCalculated by ExcelEach pathway contains its cost, duration and probability
![Page 56: REPLIDERM Inc. · GROUP 8 Tiwalade Ashaye, Joseph Azzarello, Ben Fairbanks, Mitch Hargis, Krupa Patel, Holap Tang . OVERVIEW zBackground/Review of current conditions ... 220 50 C](https://reader035.vdocuments.site/reader035/viewer/2022071006/5fc33613a3ab2c04576459bb/html5/thumbnails/56.jpg)
Comparison of different set of experiments
0%
10%
20%
30%
40%
50%
60%
70%
80%
90%
100%
$(400,000,000)
$(300,000,000)
$(200,000,000)
$(100,000,000)
$- $100,000,000 $200,000,000 $300,000,000
NPW
Prob
abili
ty
Set CSet BSet A
![Page 57: REPLIDERM Inc. · GROUP 8 Tiwalade Ashaye, Joseph Azzarello, Ben Fairbanks, Mitch Hargis, Krupa Patel, Holap Tang . OVERVIEW zBackground/Review of current conditions ... 220 50 C](https://reader035.vdocuments.site/reader035/viewer/2022071006/5fc33613a3ab2c04576459bb/html5/thumbnails/57.jpg)
Comparsion of different number of personnel
0%
10%
20%
30%
40%
50%
60%
70%
80%
90%
100%
$(450,000,000)
$(350,000,000)
$(250,000,000)
$(150,000,000)
$(50,000,000)
$50,000,000 $150,000,000
$250,000,000
$350,000,000
NPW
Prob
abili
ty
3 Tech. Set A5 Tech. Set B7 Tech. Set C
![Page 58: REPLIDERM Inc. · GROUP 8 Tiwalade Ashaye, Joseph Azzarello, Ben Fairbanks, Mitch Hargis, Krupa Patel, Holap Tang . OVERVIEW zBackground/Review of current conditions ... 220 50 C](https://reader035.vdocuments.site/reader035/viewer/2022071006/5fc33613a3ab2c04576459bb/html5/thumbnails/58.jpg)
Option to Chose
1 Ph.D. and 7 technicians
Perform test set A
![Page 59: REPLIDERM Inc. · GROUP 8 Tiwalade Ashaye, Joseph Azzarello, Ben Fairbanks, Mitch Hargis, Krupa Patel, Holap Tang . OVERVIEW zBackground/Review of current conditions ... 220 50 C](https://reader035.vdocuments.site/reader035/viewer/2022071006/5fc33613a3ab2c04576459bb/html5/thumbnails/59.jpg)
Justification
Different kinds of failure may occur.The easiest problem to fix is one that does not occur.Costs escalate rapidly with every time a product must be re-evaluated by the FDA.
![Page 60: REPLIDERM Inc. · GROUP 8 Tiwalade Ashaye, Joseph Azzarello, Ben Fairbanks, Mitch Hargis, Krupa Patel, Holap Tang . OVERVIEW zBackground/Review of current conditions ... 220 50 C](https://reader035.vdocuments.site/reader035/viewer/2022071006/5fc33613a3ab2c04576459bb/html5/thumbnails/60.jpg)
BUSINESS PLANBUSINESS PLAN
![Page 61: REPLIDERM Inc. · GROUP 8 Tiwalade Ashaye, Joseph Azzarello, Ben Fairbanks, Mitch Hargis, Krupa Patel, Holap Tang . OVERVIEW zBackground/Review of current conditions ... 220 50 C](https://reader035.vdocuments.site/reader035/viewer/2022071006/5fc33613a3ab2c04576459bb/html5/thumbnails/61.jpg)
Cost Evaluation
Direct cost - $ 8,960,000Equipment cost, Installation cost, Building & facility cost, Service charges, Raw material cost, Quality control
Indirect cost - $ 350,120,000FDA cost, Engineering and supervision
FCI FCI →→ $ 359,079,000$ 359,079,000
![Page 62: REPLIDERM Inc. · GROUP 8 Tiwalade Ashaye, Joseph Azzarello, Ben Fairbanks, Mitch Hargis, Krupa Patel, Holap Tang . OVERVIEW zBackground/Review of current conditions ... 220 50 C](https://reader035.vdocuments.site/reader035/viewer/2022071006/5fc33613a3ab2c04576459bb/html5/thumbnails/62.jpg)
Business Goal
Obtain the major part of research cost from following sources
- NIH, NSF, CDCProduction of new allograft Repliderm with the rate of 2220 sheets/monthBreakeven in 2-3 years
![Page 63: REPLIDERM Inc. · GROUP 8 Tiwalade Ashaye, Joseph Azzarello, Ben Fairbanks, Mitch Hargis, Krupa Patel, Holap Tang . OVERVIEW zBackground/Review of current conditions ... 220 50 C](https://reader035.vdocuments.site/reader035/viewer/2022071006/5fc33613a3ab2c04576459bb/html5/thumbnails/63.jpg)
Demand in the Market
0.0E+00
2.0E+06
4.0E+06
6.0E+06
8.0E+06
1.0E+07
Year 1 Year 2 Year 3 Year 4 Year 5
Burn
Wound
Ulcers
Production
Req
uire
d sh
eets
/yea
r
![Page 64: REPLIDERM Inc. · GROUP 8 Tiwalade Ashaye, Joseph Azzarello, Ben Fairbanks, Mitch Hargis, Krupa Patel, Holap Tang . OVERVIEW zBackground/Review of current conditions ... 220 50 C](https://reader035.vdocuments.site/reader035/viewer/2022071006/5fc33613a3ab2c04576459bb/html5/thumbnails/64.jpg)
Current Market Demand
Market Demand Model
)( 1211 dDpdp −= α (t, x)β (t, x)
0
0.2
0.4
0.6
0.8
1
1.2
0 2 4 6 8 10 12
Years
α
βD – Total Production Demand –500,000
d1– REPLIDERM Demand
p1 – REPLIDERM Price/sheet
p2 – Competitor's Price/sheet
x - Marketing
![Page 65: REPLIDERM Inc. · GROUP 8 Tiwalade Ashaye, Joseph Azzarello, Ben Fairbanks, Mitch Hargis, Krupa Patel, Holap Tang . OVERVIEW zBackground/Review of current conditions ... 220 50 C](https://reader035.vdocuments.site/reader035/viewer/2022071006/5fc33613a3ab2c04576459bb/html5/thumbnails/65.jpg)
Production rate & sale price
∑=
=−3
111
ii FCIPCdp
Product price = $ 1870 / sheetProduction rate = 2220 sheets / month (1st yr)
Production Rate
0
50000
100000
150000
200000
250000
0 1 2 3 4 5 6
Year
Num
ber
of s
heet
s
![Page 66: REPLIDERM Inc. · GROUP 8 Tiwalade Ashaye, Joseph Azzarello, Ben Fairbanks, Mitch Hargis, Krupa Patel, Holap Tang . OVERVIEW zBackground/Review of current conditions ... 220 50 C](https://reader035.vdocuments.site/reader035/viewer/2022071006/5fc33613a3ab2c04576459bb/html5/thumbnails/66.jpg)
Marketing
Product distribution- 56 hospitals every six months
3 national conferences annually2 International conferences annuallyTradeshows and fellowship
![Page 67: REPLIDERM Inc. · GROUP 8 Tiwalade Ashaye, Joseph Azzarello, Ben Fairbanks, Mitch Hargis, Krupa Patel, Holap Tang . OVERVIEW zBackground/Review of current conditions ... 220 50 C](https://reader035.vdocuments.site/reader035/viewer/2022071006/5fc33613a3ab2c04576459bb/html5/thumbnails/67.jpg)
Cumulative Cash Position
Increase in production rate following the model- Initially 26645 sheet / yearIncrease in staff by 25% Increase Marketing by 10-20%
![Page 68: REPLIDERM Inc. · GROUP 8 Tiwalade Ashaye, Joseph Azzarello, Ben Fairbanks, Mitch Hargis, Krupa Patel, Holap Tang . OVERVIEW zBackground/Review of current conditions ... 220 50 C](https://reader035.vdocuments.site/reader035/viewer/2022071006/5fc33613a3ab2c04576459bb/html5/thumbnails/68.jpg)
Cumulative Cash Position Forecast
-1000
-500
0
500
1000
1500
2000
2500
3000
3500
-16 -14 -12 -10 -8 -6 -4 -2 0 2 4 6 8 10
Year
Cum
ulat
ive
cash
pos
ition
($ M
M)
![Page 69: REPLIDERM Inc. · GROUP 8 Tiwalade Ashaye, Joseph Azzarello, Ben Fairbanks, Mitch Hargis, Krupa Patel, Holap Tang . OVERVIEW zBackground/Review of current conditions ... 220 50 C](https://reader035.vdocuments.site/reader035/viewer/2022071006/5fc33613a3ab2c04576459bb/html5/thumbnails/69.jpg)
Location Selection
Factors considered- NIH funding- Employment in Biotech companies- Cost of living- Number of private biotech companies- Number of Hospitals- Corporate tax rateFairfield, CA
![Page 70: REPLIDERM Inc. · GROUP 8 Tiwalade Ashaye, Joseph Azzarello, Ben Fairbanks, Mitch Hargis, Krupa Patel, Holap Tang . OVERVIEW zBackground/Review of current conditions ... 220 50 C](https://reader035.vdocuments.site/reader035/viewer/2022071006/5fc33613a3ab2c04576459bb/html5/thumbnails/70.jpg)
Conclusion
Control release delivery systemPre-FDA testing by 8 personnel Testing Set ASale price $1870 / sheet Production rate 27000 sheets / year
![Page 71: REPLIDERM Inc. · GROUP 8 Tiwalade Ashaye, Joseph Azzarello, Ben Fairbanks, Mitch Hargis, Krupa Patel, Holap Tang . OVERVIEW zBackground/Review of current conditions ... 220 50 C](https://reader035.vdocuments.site/reader035/viewer/2022071006/5fc33613a3ab2c04576459bb/html5/thumbnails/71.jpg)
Acknowledgements
Dr. BagajewiczDr. SikavitsasDr. Yannas (Integra LifeScience)Timothy King and Charles Patrick (University of Texas)
![Page 72: REPLIDERM Inc. · GROUP 8 Tiwalade Ashaye, Joseph Azzarello, Ben Fairbanks, Mitch Hargis, Krupa Patel, Holap Tang . OVERVIEW zBackground/Review of current conditions ... 220 50 C](https://reader035.vdocuments.site/reader035/viewer/2022071006/5fc33613a3ab2c04576459bb/html5/thumbnails/72.jpg)
QUESTIONS?????QUESTIONS?????